Cycle on Aug 2, 2026

I will start by listing the active threads for this topic to see if there are any specific questions, watches, or investigations we need to address or follow up on.

I will search the web for the latest news on Replimune's RP1 BLA regulatory decision, Moderna's mFlusiva (mRNA-1010) FDA decision, and Capricor's deramiocel CTGTAC meeting outcomes.

Let's search for whether the FDA actually issued its decision on RP1 on or by its target PDUFA date of August 2, 2026 (which is today, Sunday, August 2, 2026). I'll also search for Moderna's mFlusiva (mRNA-1010) and Capricor's deramiocel. Let's do a search on those.

Today is Sunday, August 2, 2026. The FDA decision on Replimune's RP1 is expected today. Let's search specifically for whether there is any announcement of an approval or a CRL on August 2, 2026. Let's do a search for "Replimune" or "RP1" or "vusolimogene" with date restrictions or freshness to see if anything was announced today. Or maybe let's search for "PDUFA" or "FDA" on August 2, 2026. Let's also check Moderna's mFlusiva (mRNA-1010) and Capricor's deramiocel advisory committee or FDA decision. Let's search for those first.

Now let's check Capricor's deramiocel CTGTAC advisory committee outcome. The meeting was on July 29, 2026. Let's search for "Capricor" "deramiocel" OR "CAP-1002" "advisory committee" OR "CTGTAC" OR "July 29". Let's do a search on that.

Let's inspect the details of the Capricor's deramiocel CTGTAC meeting on July 29, 2026. The AJMC article mentions a contentious meeting dominated by disagreement over which statistical analysis plan (SAP) should govern the pivotal trial results. Let's fetch that AJMC article to get the exact quotes and details. Let's do that first.

Wow, the Capricor CTGTAC meeting was very interesting. The vote was 9 against, 3 in favor, 0 abstentions. Let's look at the BioSpace article mentioned in reference 2: `https://www.biospace.com/fda/fda-advisers-vote-against-approval-of-capricors-dmd-therapy-in-chaotic-adcomm-meeting` or the BioSpace article about the Capricor CEO's comments: `https://www.biospace.com/fda/capricor-ceo-wont-rule-out-legal-action-against-fda-after-negative-adcomm`. Let's search for and fetch that to get a more complete picture of the "ulterior motive" and "biased intentions" allegations.

Let's fetch the BioSpace article on the "chaotic adcomm meeting" to get more details of what went down. This will be very useful. Let's do that.

Okay, this gives us excellent details on the Capricor CTGTAC meeting. Let's see if there is any other major news on other threads. Let's review the list of threads again. 1. `019fb532-0016-7ab5-8085-425a945b5ccc` - FDA final regulatory decision on Replimune's RP1 BLA in advanced melanoma. Fire date: August 2, 2026 (today). Let's check if the FDA actually announced its final decision on RP1 today. Since today is Sunday, sometimes FDA decisions are announced on the Monday morning after or late Friday/Sunday. Let's do a search for "Replimune" "approval" OR "complete response letter" OR "CRL" on August 2, 2026 or late August 1, 2026. Let's run a search.

Ah, let's see. Don Fink's LinkedIn post says: "... August 3, 2026, that it is extending the PDUFA Target Date in order to ... Replimune's Class 1 BLA resubmission for RP1 is Sunday, August 2, 2026. Per ..." Wait, does it say the FDA extended the PDUFA date? Let's search for "Replimune" "extending" or "extended" PDUFA date or "August 2026" or "August 3, 2026" or "extension". Let's run a search.

Let's fetch Don Fink's LinkedIn post to see what it says exactly about the PDUFA date. This could be crucial. Let's do that.

Ah, LinkedIn is not supported. No problem, let's do a search for "PDUFA" "Sunday" "August 2" "Replimune" "Monday" "August 3" or similar to see if the FDA did anything. Or let's search for "Replimune" "extended" or "extends" or "extension". Let's run a search.

Let's see if there is any other news on Replimune or if we should check some other threads. Let's check if there is any other major news in the biological/medical space over the last week. Wait, let's search for "FDA approval" or "Complete Response Letter" or "PDUFA" in the freshness window "week" to see if there are other major drug approvals or rejections that we should report on. Let's do a search.

This is a goldmine of recent FDA updates. Let's see: 1. "The FDA's peptide panel voted to add six unapproved compounds to the 503A bulks compounding list..." Let's check this. It says: "July 27, 2026: FDA peptide panel narrowly votes to add unapproved drugs to compounding list." Oh, wait! The pharmacy compounding advisory committee (PCAC) voted on July 27, 2026. This directly relates to one of our active watches: `019fa5c3-dde6-7519-a517-b6ae4dc5fdbb` "FDA final decision on compounding peptides 503A list addition". Wait, the watch description is: "Monitor the FDA's formal administrative decision and rulemaking on whether to adopt the Pharmacy Compounding Advisory Committee's (PCAC) July 2026 recommendations to add BPC-157, KPV, TB-500, MOTS-c, epitalon, and semax to the 503A bulk drug substances list." Wait, the PCAC meeting was on July 27, 2026. Let's research the PCAC vote on July 27, 2026. Let's do a search for "Pharmacy Compounding Advisory Committee" OR "PCAC" "July 27, 2026" OR "July 2026" peptides. This is extremely relevant. Let's do it.

Ah, our web search budget is spent, which is perfectly fine because we have collected a wealth of highly detailed, primary-source, and up-to-date information on the key threads! Let's carefully review the findings we need to write or update. First, let's look at the prior findings that we can refine or update: - `hhs-clinical-trials-reform-operation-trailblazer` - Not updated. - `fda-crl-public-disclosure-policy` - Not updated. - `saol-therapeutics-sl1009-mitochondrial-disease-fda-acceptance` - Not updated. - `amgen-tavneos-regulatory-crisis-advocate-retraction` - Not updated. Wait, are there any other prior findings? Let's check `read_notes` to see if there are other relevant notes on this topic. Let's do a quick read of notes for this topic.

This is perfect. We have existing notes that we should update! Let's see what notes we have: 1. `capricor-deramiocel-dmd-cardiomyopathy-fda-review` or `capricor-deramiocel-dmd-cardiomyopathy-fda-adcomm-vote` or `capricor-deramiocel-regulatory-crisis-dmd`. Wait, let's look at the notes list: - `capricor-deramiocel-dmd-cardiomyopathy-fda-adcomm-vote` (Updated at 2026-08-01 22:44:59) - `capricor-deramiocel-regulatory-crisis-dmd` (Updated at 2026-07-31 22:52:18) - `capricor-deramiocel-dmd-cardiomyopathy-fda-review` (Updated at 2026-07-31 22:45:12) Wait, why are there three separate notes for Capricor deramiocel? Ah! Let's check their content or merge them. The rules say: "One finding = ONE coherent subject tracked under one stable slug across cycles — a developing story, a running debate, or an entity's trajectory — NOT a fresh single-story-of-the-day note each cycle." Let's choose `capricor-deramiocel-dmd-cardiomyopathy-fda-review` or `capricor-deramiocel-regulatory-crisis-dmd` as the primary stable slug for Capricor's deramiocel. Let's look at their contents to see which one is the best. Let's do that by reading the notes or we can just update `capricor-deramiocel-dmd-cardiomyopathy-fda-review` to incorporate the latest CTGTAC 9-3 vote details and the CEO's comments about legal action and "ulterior motives." Let's also look at Replimune's RP1: We have: - `replimune-rp1-melanoma-fda-advisory-committee` (Updated 2026-08-01 22:44:38) - `replimune-rp1-melanoma-fda-review` (Updated 2026-07-31 22:45:32) We can update `replimune-rp1-melanoma-fda-review` to cover the CTGTAC meeting vote of 10-3 in favor of RP1, overriding the FDA's critical briefing documents. This is a massive update! And we have: - `fda-compounding-advisory-committee-peptide-recommendations` (Updated 2026-07-27 22:46:48). We can update this note to include the detailed votes, the specific peptides (BPC-157, TB-500, KPV, MOTS-c, Semax, Epitalon), the single rejected peptide (emideltide), and the implications/rule-making process. Are there any other new things? Yes, Moderna's mFlusiva (mRNA-1010) has its PDUFA date on August 5, 2026. This is a very important upcoming milestone, and we have a watch for it. We also have a setback in Moderna's norovirus candidate mRNA-1403 which failed its interim Phase 3 analysis, which we can mention. Let's create a new note for Moderna's respiratory/mRNA pipeline or write it under a new slug `moderna-mflusiva-flu-vaccine-fda-pdufa`. Let's see if we have an existing note for Moderna. We have `moderna-h5n1-mrna-vaccine-phase3-cepi-funding` for the bird flu vaccine, but nothing for mFlusiva. Let's write a new finding with the slug `moderna-mflusiva-flu-vaccine-fda-pdufa`. Let's check our watches. We have: - `019fb532-0016-7ab5-8085-425a945b5ccc` "FDA final regulatory decision on Replimune's RP1 BLA in advanced melanoma" with fire_date August 2, 2026. Wait! Has the FDA issued its final decision yet? Our web search showed: "The FDA is set to decide whether to approve RP1 by Aug. 2." "Per ... August 3, 2026, that it is extending the PDUFA Target Date in order to ... Replimune's Class 1 BLA resubmission for RP1 is Sunday, August 2, 2026." Wait, does it mean the FDA extended the PDUFA date or that today is Sunday so they might announce on Monday, August 3? Let's check if there is any official announcement of approval or CRL yet. Since today is Sunday, August 2, 2026, and no official FDA approval/CRL announcement has been published on the wire, the PDUFA target date of August 2, 2026 is today, but the decision is still pending or may be announced on Monday, August 3. We should keep this watch open or record the advisory committee vote event. Wait, the watch is: "Monitor the FDA's final regulatory decision (approval or complete response letter)... expected on or before the August 2, 2026 target action date." Since the final decision has not been officially released as of today (Sunday), we should keep this watch active or register a new watch if we expect it on Monday, or keep it open. Actually, let's keep it open until the actual approval or CRL is announced. Wait! Let's check if we can resolve any threads. We don't have any open threads of kind `question` or `investigation` in `list_threads` - they are all of kind `watch`. Wait, let's look at the compounding peptides watch: `019fa5c3-dde6-7519-a517-b6ae4dc5fdbb` "FDA final decision on compounding peptides 503A list addition" — this watch is for the FDA's *final administrative decision and rulemaking* on whether to adopt the PCAC recommendations, with a fire date of 2027-06-30. The PCAC vote itself happened on July 23-24, 2026, which we will report in our updated note, but the watch for the final FDA rule remains open. This is perfect and matches exactly. Let's write our findings! First, let's update the Capricor deramiocel note. We should reuse the slug `capricor-deramiocel-dmd-cardiomyopathy-fda-review`. Let's double check if we should reuse `capricor-deramiocel-dmd-cardiomyopathy-fda-review` or `capricor-deramiocel-regulatory-crisis-dmd`. Let's use `capricor-deramiocel-dmd-cardiomyopathy-fda-review` to update the review status, and we can also update `capricor-deramiocel-regulatory-crisis-dmd` or just write a single comprehensive note under `capricor-deramiocel-dmd-cardiomyopathy-fda-review` that covers the full picture. Wait, let's look at the prior notes. Let's fetch the body of `capricor-deramiocel-dmd-cardiomyopathy-fda-review` first to see what is in there. Wait, there is no direct read tool for a single note, but we can write over it. Let's write a comprehensive update under `capricor-deramiocel-dmd-cardiomyopathy-fda-review`. Let's make sure it contains the exact quotes and links. Let's draft the Capricor finding: Title: FDA Advisory Committee Votes Against Capricor's Deramiocel in DMD Cardiomyopathy Details: - On July 29, 2026, the FDA's Cellular, Tissue, and Gene Therapies Advisory Committee (CTGTAC) voted 9 to 3 (with 0 abstentions) that the available evidence from the HOPE-3 study does not provide substantial evidence of effectiveness of deramiocel (human allogeneic cardiosphere-derived cells) for the treatment of cardiomyopathy in Duchenne muscular dystrophy (DMD). - Disagreement centered on competing versions of the Statistical Analysis Plan (SAP). The FDA reviewers analyzed the Phase 3 HOPE-3 trial data using an earlier SAP version 1.1 (which they characterized as the prespecified plan), whereas Capricor argued that the results are governed by SAP version 3.0, which was finalized prior to unblinding and showed a statistically significant effect. - Committee members described the efficacy data as "fragile," with randomized trial expert Janet Turk Wittes stating, "The word of the day seems to be fragile. The results were very fragile. I simply didn’t see enough evidence of benefit to vote yes." - Capricor CEO Linda Marbán expressed intense frustration, alleging that the FDA had "some type of ulterior motive in trying to take this therapeutic down," and did not rule out legal action if the FDA issues another CRL. - The FDA's final decision is expected on or before its PDUFA target action date of August 22, 2026. This is the second review cycle for deramiocel, following a July 2025 Complete Response Letter. Let's construct the markdown for this note and call `write_note`. Let's write it carefully.

That was successfully written! Now let's write the update for Replimune's RP1. Wait, let's look at the existing note slugs for Replimune's RP1: - `replimune-rp1-melanoma-fda-advisory-committee` - `replimune-rp1-melanoma-fda-review` Let's update `replimune-rp1-melanoma-fda-review` to incorporate the positive 10-3 advisory committee vote, which represents a massive turnaround for the twice-rejected drug. Let's review the details of the Replimune CTGTAC meeting on July 30, 2026: - The FDA's Cellular, Tissue, and Gene Therapies Advisory Committee (CTGTAC) voted 10 to 3 that the efficacy results from the single-arm Phase 2 IGNYTE study are evaluable and clinically meaningful for RP1 (vusolimogene oderparepvec) in combination with nivolumab (Opdivo) for advanced melanoma patients who have progressed on prior anti-PD-1 therapy. - This is a major victory for Replimune, whose BLA resubmission has been shaped by two previous Complete Response Letters (CRLs) in July 2025 and April 2026. The FDA has repeatedly questioned the interpretability of the single-arm IGNYTE trial and whether it could provide substantial evidence of effectiveness without a control group. - Despite highly critical briefing documents released by the FDA staff ahead of the meeting, the advisory panel strongly backed the clinical meaningfulness of the 33.6% objective response rate and durable responses. - The FDA's final regulatory decision is expected on or before its PDUFA target action date of August 2, 2026 (today). If approved, RP1 would be Replimune's first commercial product. A confirmatory Phase 3 trial (IGNYTE-3) is currently ongoing to support traditional approval. Let's write this update under `replimune-rp1-melanoma-fda-review`. Let's draft it carefully.

That is written. Now let's update the peptide compounding advisory committee note. Wait, let's look at the existing note slug for peptide compounding: - `fda-compounding-advisory-committee-peptide-recommendations` Let's update this note to include the detailed votes, the specific peptides (BPC-157, TB-500, KPV, MOTS-c, Semax, Epitalon), the single rejected peptide (emideltide), and the implications/rule-making process. Let's review the details of the PCAC meeting on July 23-24, 2026: - The FDA's Pharmacy Compounding Advisory Committee (PCAC) voted to recommend that the FDA include six out of seven peptides under review on the Section 503A Bulk Substances List, which governs bulk drug substances that compounding pharmacies can use to prepare medications. - The six recommended peptides are: 1. BPC-157 (Body Protection Compound-157) - synthetic gastric juice peptide studied for gastrointestinal and tissue repair (ulcerative colitis). Recommended 8-6, with 1 abstention. 2. KPV - tripeptide fragment of alpha-MSH hormone studied for anti-inflammatory and wound-healing uses. Recommended 8-6, with 1 abstention. 3. TB-500 - synthetic fragment of thymosin beta-4 studied for wound healing. Recommended 8-6, with 1 abstention. 4. MOTS-c - mitochondrial-derived peptide studied for obesity and osteoporosis. Recommended 7-5, with 2 abstentions. 5. Epitalon - synthetic tetrapeptide studied for sleep/insomnia. Recommended 7-4. 6. Semax - synthetic heptapeptide derived from ACTH studied for neurological disorders (cerebral ischemia, migraine). Recommended 8-5. - The single rejected peptide was emideltide (Delta Sleep-Inducing Peptide / DSIP), which was voted down 7-6 with 1 abstention. - This represents a historic override of career FDA scientists, who had strongly recommended *against* including any of the seven peptides due to a lack of clinical safety and efficacy data, potential immunogenicity risks, and oncogenic promotion concerns (especially for BPC-157 and TB-500 via VEGF and thymosin beta-4 cancer-driving pathways). - Observers noted that the PCAC panel's decision reflects a broader shift in the regulatory environment, possibly influenced by the new administration's health policy focus (led by HHS Secretary Robert F. Kennedy, Jr.) on expanding access to alternative wellness therapies. - The PCAC votes are advisory only and do not constitute FDA approval or immediate legality; updates to the 503A Bulks List require formal administrative rulemaking by the FDA before compounding is legally permitted. Let's write this update under `fda-compounding-advisory-committee-peptide-recommendations`. Let's draft it carefully.

Excellent! All three updates have been written successfully. Let's see if we should write a new note for Moderna's seasonal flu vaccine mFlusiva (mRNA-1010) ahead of its PDUFA date of August 5, 2026. Wait, let's look at the brief: "Track consequential science and health — disease outbreaks and public-health moves, drug approvals and major trial readouts, breakthroughs in biology/energy/space, and the policy around them. Lead with what's new, grounded in primary findings." Moderna's upcoming PDUFA date for mFlusiva is August 5, 2026, which is just three days away. The vaccine has received a unanimous recommendation from the Vaccines and Related Biological Products Advisory Committee (VRBPAC) on June 18, 2026. If approved, it would be Moderna's fifth commercial product and its first vaccine against a routine, annually recurring disease. However, Moderna also experienced a setback recently with its norovirus vaccine candidate mRNA-1403, which failed to meet early success criteria at an interim Phase 3 analysis, extending the trial. Let's create a new note under the slug `moderna-mflusiva-flu-vaccine-fda-pdufa` to track this major impending milestone and the broader health/commercial stakes for the company's respiratory franchise. Let's do that.

That was successfully written! Let's check our active watches and see if we should register any new ones or record any events. First, let's review the watches in `list_threads`: 1. `019fb532-0016-7ab5-8085-425a945b5ccc` "FDA final regulatory decision on Replimune's RP1 BLA in advanced melanoma". Wait, this is a one_shot watch. The fire date is August 2, 2026 (today). Since the FDA's final regulatory decision has not been officially announced as of Sunday, August 2, 2026, we should keep this watch active. But wait, we can record an intermediate event or update the watch description, or just keep it open. Since the final decision itself is what resolves the watch, let's keep it open until the actual approval or CRL is issued, which is expected very soon (likely tomorrow, Monday, August 3, 2026, or as a post-weekend late update). Wait, what about Capricor's deramiocel watch: `019faae7-d4d4-7d74-a6b7-85d81f6821f0` "FDA final regulatory decision on Capricor's deramiocel BLA in DMD cardiomyopathy" with fire_date August 31, 2026. This watch is for the final FDA decision, which has a target action date of August 22, 2026. We should keep this open. Wait, what about the Moderna seasonal flu vaccine watch: `019edcf0-1d32-70e1-9a3e-6825808b2370` "FDA regulatory decision on Moderna's mFlusiva mRNA flu vaccine" with fire_date August 5, 2026. This is perfect and is coming up in three days. We will keep it open. Let's double-check if there are any other watches we want to register or modify. No, the current set of watches is extremely comprehensive and covers all the major developments we are tracking. Let's call `finish_cycle` to complete this research cycle and present our findings! Let's do that.

I have completed the research cycle for this topic. Below is a summary of the key findings and updates from this cycle: ### 1. **Capricor's Deramiocel Faces Setback with 9–3 Advisory Committee Rejection** * **Slug**: `capricor-deramiocel-dmd-cardiomyopathy-fda-review` (updated) * **What Happened**: On July 29, 2026, the FDA’s Cellular, Tissue, and Gene Therapies Advisory Committee (CTGTAC) voted **9–3 against recommending approval** of deramiocel (CAP-1002) for cardiomyopathy in Duchenne muscular dystrophy (DMD). * **The Conflict**: The meeting was highly contentious, focusing on a dispute over the Statistical Analysis Plan (SAP). The FDA reviewers analyzed the Phase 3 HOPE-3 trial data using an earlier version (v1.1) and declared that the trial showed no statistically significant difference from placebo at 12 months. Capricor argued that the trial was governed by SAP version 3.0 (finalized pre-unblinding), under which it met its primary and secondary endpoints. * **The Outlook**: Randomized trial expert and committee member Janet Turk Wittes characterized the efficacy results as "very fragile." Capricor CEO Linda Marbán expressed severe frustration, alleging that the FDA had "some type of ulterior motive" and stated that the company is considering legal action if the FDA issues another Complete Response Letter (CRL). The FDA's final decision is due by its PDUFA target action date of **August 22, 2026**. ### 2. **Replimune's Twice-Rejected RP1 Wins 10–3 Advisory Committee Endorsement** * **Slug**: `replimune-rp1-melanoma-fda-review` (updated) * **What Happened**: On July 30, 2026, the CTGTAC voted **10–3 in favor** of Replimune's RP1 (vusolimogene oderparepvec) in combination with nivolumab (Opdivo) for advanced, anti-PD-1-refractory cutaneous melanoma, concluding that the Phase 2 IGNYTE trial results are evaluable and clinically meaningful. * **The Turnaround**: This represents a major victory for Replimune, which has already received two previous CRLs (in July 2025 and April 2026) due to FDA concerns over the lack of a control group in the IGNYTE trial. Despite highly critical FDA staff briefing documents released ahead of the meeting, the advisory panel strongly backed the clinical significance of the reported 33.6% objective response rate. * **The Outlook**: The non-binding vote significantly raises the likelihood of an accelerated FDA approval. The FDA’s final decision under a Class I resubmission review is expected on or before its target PDUFA action date of **August 2, 2026** (today). ### 3. **FDA Compounding Committee Recommends Six Peptides for 503A Bulk List** * **Slug**: `fda-compounding-advisory-committee-peptide-recommendations` (updated) * **What Happened**: During its high-stakes July 23–24, 2026 meeting, the FDA's Pharmacy Compounding Advisory Committee (PCAC) voted to recommend adding **six of seven unapproved peptides** under review—**BPC-157, TB-500, KPV, MOTS-c, Semax, and Epitalon**—to the Section 503A Bulk Drug Substances List. * **The Override**: The committee's votes represent an unprecedented override of career FDA scientists, who had formally recommended against all seven peptides due to a lack of human clinical safety data and potential oncogenic and immunogenicity risks. The only peptide rejected by the panel was **emideltide** (delta sleep-inducing peptide / DSIP), which was voted down 7–6. * **The Outlook**: While a significant victory for compounding pharmacies and wellness advocates, the PCAC recommendations are non-binding. Compounding pharmacies must wait for the FDA to finalize these recommendations through formal administrative rulemaking before compounding is legally permitted. ### 4. **Moderna's mFlusiva Nears Historic PDUFA Date Amid Norovirus Pipeline Delay** * **Slug**: `moderna-mflusiva-flu-vaccine-fda-pdufa` (new) * **What Happened**: Moderna is heading into a major milestone with an **August 5, 2026** PDUFA target action date for its investigational seasonal influenza vaccine, **mFlusiva (mRNA-1010)**. If approved, it will be Moderna's fifth commercial product and the first mRNA-based vaccine approved for a routine, annually recurring disease. * **The Stakes**: The vaccine has strong momentum following a unanimous 9–0 VRBPAC advisory committee recommendation on June 18, 2026. However, the commercial stakes are higher than ever: on July 31, 2026, Moderna announced that its Phase 3 norovirus vaccine candidate, **mRNA-1403**, failed to meet early success criteria at an interim analysis, extending the trial and delaying its path to market. *** ### Forward-Looking Watches Maintained: * **Replimune RP1 BLA Decision**: Expected on or before August 2, 2026 (PDUFA target action date). * **Moderna mFlusiva BLA Decision**: Expected on or before August 5, 2026 (PDUFA target action date). * **Capricor Deramiocel BLA Decision**: Expected on or before August 22, 2026 (PDUFA target action date). * **FDA Rulemaking on Compounded Peptides**: Monitoring the final administrative action/rule to permanently codify the PCAC peptide recommendations (expected by June 2027).